Prognostic factors in ALS: a comparison between Germany and China

[1]  S. Klebe,et al.  Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial , 2018, The Lancet Neurology.

[2]  A. Gitler,et al.  The epidemiology and genetics of Amyotrophic lateral sclerosis in China , 2018, Brain Research.

[3]  G. Nagel,et al.  Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany , 2018, Journal of Neurology.

[4]  Shenghan Zhou,et al.  Using the Capture-Recapture Method to Estimate the Incidence of Amyotrophic Lateral Sclerosis in Beijing, China , 2018, Neuroepidemiology.

[5]  G. Nagel,et al.  The concept and diagnostic criteria of primary lateral sclerosis , 2017, Acta neurologica Scandinavica.

[6]  Y. Itoyama,et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.

[7]  G. Nagel,et al.  Epidemiology of amyotrophic lateral sclerosis in Southern Germany , 2017, Journal of Neurology.

[8]  Zhi-rui Zhou,et al.  Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  W. Ye,et al.  Association between diabetes and amyotrophic lateral sclerosis in Sweden , 2015, European journal of neurology.

[10]  Rui Huang,et al.  Clinical features of amyotrophic lateral sclerosis in south-west China , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[11]  D. Fan,et al.  Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  Y. Jiang,et al.  Epidemiological characteristics of motor neuron disease in Chinese patients , 2014, Acta neurologica Scandinavica.

[13]  J. Lou,et al.  Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial , 2014, The Lancet.

[14]  A. Al-Chalabi,et al.  The epidemiology of ALS: a conspiracy of genes, environment and time , 2013, Nature Reviews Neurology.

[15]  A. Chiò,et al.  Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature , 2013, Neuroepidemiology.

[16]  M. York,et al.  ALS disease onset may occur later in patients with pre‐morbid diabetes mellitus , 2010, European journal of neurology.

[17]  Lucette Lacomblez,et al.  Impaired glucose tolerance in patients with amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[18]  Fumiaki Tanaka,et al.  Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis , 2009, Journal of the Neurological Sciences.

[19]  K. Thennarasu,et al.  Clinical characteristics and survival pattern of 1153 patients with amyotrophic lateral sclerosis: Experience over 30 years from India , 2008, Journal of the Neurological Sciences.

[20]  V. Meininger,et al.  Dyslipidemia is a protective factor in amyotrophic lateral sclerosis , 2008, Neurology.

[21]  P. Preux,et al.  Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters , 2006, Neurodegenerative Diseases.

[22]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[23]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[24]  D. Sautereau,et al.  Nutritional status is a prognostic factor for survival in ALS patients , 1999, Neurology.

[25]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[26]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[27]  W. Hagamen,et al.  Adaptation of evoked auditory potentials: a midbrain through frontal lobe map in the unanesthetized cat. , 1969, Brain research.

[28]  Angela M. Malek,et al.  The epidemiology of amyotrophic lateral sclerosis. , 2016, Handbook of clinical neurology.

[29]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.